Cargando…
Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT
AIMS: Non‐alcoholic fatty liver disease leads to progressive liver fibrosis and appears to be a frequent co‐morbid disease in heart failure with preserved ejection fraction (HFpEF). It is well known that liver fibrosis severity predicts future liver‐related morbidity and mortality, but its impact on...
Autores principales: | Peters, Anthony E., Pandey, Ambarish, Ayers, Colby, Wegermann, Kara, McGarrah, Robert W., Grodin, Justin L., Abdelmalek, Manal F., Bekfani, Tarek, Blumer, Vanessa, Diehl, Anna Mae, Moylan, Cynthia A., Fudim, Marat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006722/ https://www.ncbi.nlm.nih.gov/pubmed/33586354 http://dx.doi.org/10.1002/ehf2.13250 |
Ejemplares similares
-
Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction
por: Salah, Husam M., et al.
Publicado: (2021) -
Serum Metabolites Are Associated With HFpEF in Biopsy‐Proven Nonalcoholic Fatty Liver Disease
por: Wegermann, Kara, et al.
Publicado: (2023) -
Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries
por: Fudim, Marat, et al.
Publicado: (2021) -
Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial
por: Pandey, Ambarish, et al.
Publicado: (2018) -
Identifying a low‐flow phenotype in heart failure with preserved ejection fraction: a secondary analysis of the RELAX trial
por: Patel, Kershaw V., et al.
Publicado: (2019)